As previously reported, Stephens initiated coverage of Option Care Health (OPCH) with an Overweight rating and $40 price target The company represents an established equity within the Healthcare Services universe underlying its leading, pure-play exposure to infusion services, the analyst tells investors in a research note. Option Care Health is well positioned in the value chain given its alternative-site/home-based orientation offering cost-bending benefits, while structurally exhibiting a premium organic growth baseline vs. traditional settings, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPCH:
- Option Care Health initiated with an Overweight at Stephens
- Option Care Health price target raised to $35 from $32 at BofA
- Option Care Health price target raised to $36 from $31 at Deutsche Bank
- Option Care Health: Strong Growth Prospects and Strategic Initiatives Drive Buy Rating
- Option Care Health management to meet with Truist